Jeffrey M. Lemons, MD, on Solid Tumors: Safety Data on SBRT and Immunotherapy

2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Jeffrey M. Lemons, MD, of the University of Chicago, discusses early safety and efficacy findings from a small study on pembrolizumab and multiorgan-site ablative stereotactic body radiotherapy in patients with advanced solid tumors (Abstract 20).

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.